Document Type

Article

Publication Date

7-3-2017

Identifier

DOI: 10.1080/21645515.2017.1309486; PMCID: PMC5512763

Abstract

One combined measles-mumps-rubella (MMR) vaccine without Human Serum Albumin (HSA) is currently licensed in the USA (M-M-R II; Merck, USA) and another has been developed (Priorix™ [MMR-RIT, GSK, Belgium]). In this follow-up study, children from USA or Puerto Rico, who had received one dose of M-M-R II or MMR-RIT at 12-15 months of age in the primary study (NCT00861744), were followed-up for 2 y post-vaccination. Anti-measles and anti-rubella antibodies were measured using Enzyme-Linked Immunosorbent Assay (ELISA), and anti-mumps antibodies using ELISA and plaque reduction neutralization (PRN) assays. Serious adverse events (SAEs) were recorded during the entire follow-up. The according-to-protocol (ATP) persistence cohort included 752 children (M-M-R II = 186, MMR-RIT = 566), who received primary vaccination at a mean age of 12.3 ( ± 0.67) months. 104 children were revaccinated with MMR-containing vaccines; therefore, serology results for timepoints after revaccination were excluded from the analysis. Seropositivity for measles (Year 1≥ 98.3%; Year 2≥ 99.4%) and rubella (Year 1≥ 98.9%; Year 2 = 100%) remained as high at Year 2 as at Day 42. Similarly, seropositivity for mumps determined by ELISA (Year 1≥ 90.1%; Year 2≥ 94.1%) and PRN assays (Year 1≥ 87.5%; Year 2≥ 91.7%) persisted. Thirty-three SAEs were recorded in 23 children; 2 SAEs (inguinal adenitis and idiopathic thrombocytopenic purpura) and one SAE (febrile convulsion) were considered as potentially related to MMR-RIT and M-M-R II, respectively. This study showed that antibodies against measles, mumps and rubella persisted for up to 2 y post-vaccination with either MMR vaccine in children aged 12-15 months, and that both vaccines were well-tolerated during the follow-up period.

Journal Title

Hum Vaccin Immunother

Volume

13

Issue

7

First Page

1516

Last Page

1522

MeSH Keywords

Antibodies, Neutralizing; Antibodies, Viral; Drug-Related Side Effects and Adverse Reactions; Enzyme-Linked Immunosorbent Assay; Follow-Up Studies; Humans; Immunization Schedule; Infant; Measles-Mumps-Rubella Vaccine; Neutralization Tests; Puerto Rico; Time Factors; United States; Viral Plaque Assay

Keywords

MMR vaccine; Priorix; antibody persistence; measles; mumps; rubella

Comments

Grant support

This is an open access article distributed under the terms of the Creative Commons CC BY license, which permits unrestricted use, distribution, reproduction in any medium, provided the original work is properly cited.

Publisher' Link: https://www.tandfonline.com/doi/full/10.1080/21645515.2017.1309486

Download

Share

COinS